Biotechnology financing, not acquisitions, for filling the pharma pipeline – a sustaining strategy

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.2, Iss.7, 2007-07, pp. : 917-921

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Filling the Pipeline - New Drugs for an Old Disease

Current Topics in Medicinal Chemistry, Vol. 14, Iss. 1, 2014-01 ,pp. : 110-129

Bentham Science Publishers

Access to resources Recommend Favorite

Strategies for reliable and effective ADME. Advice on a cost-effective strategy for Pharma and Biotech

Expert Opinion on Drug Safety, Vol. 3, Iss. 2, 2004-03 ,pp. : 85-87

Informa Healthcare

Access to resources Recommend Favorite

Target validation in silico: does the virtual patient cure the pharma pipeline?

By Alkema Wynand Rullmann Ton van Elsas Andrea

Expert Opinion on Therapeutic Targets, Vol. 10, Iss. 5, 2006-10 ,pp. : 635-638

Informa Healthcare

Access to resources Recommend Favorite

Why Antidiabetic Vanadium Complexes are Not in the Pipeline of “Big Pharma” Drug Research? A Critical Review

Current Medicinal Chemistry, Vol. 23, Iss. 25, 2016-08 ,pp. : 2874-2891

Bentham Science Publishers

Access to resources Recommend Favorite

Mergers and Acquisitions Dynamics in the Biotechnology Industry: What are the Key Drivers for the Genomics Sector?

By Amir-Aslani Arsia

International Journal of Pharmaceutical Medicine, Vol. 21, Iss. 2, 2007-01 ,pp. : 147-156

Adis International

Access to resources Recommend Favorite